MedTrace Logo

Mendelian Reverse Cholesterol Transport Study

NCT01782027 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2024-09-19

No results posted yet for this study

Summary

The purpose of this study is to investigate the use of radiolabeled particulate cholesterol administered intravenously in association with albumin, as a method to study reverse cholesterol transport (RCT) in people carrying mutations in genes known to affect high density lipoprotein (HDL) metabolism by analyzing changes in the tracer activity in total plasma, lipoproteins fractions and feces.

Conditions

  • Cholesterol, HDL
  • Lipid Metabolism, Inborn Errors
  • Tangier Disease
  • LCAT Deficiency
  • Cholesteryl Ester Transfer Protein (CETP) Deficiency

Interventions

DRUG

3H-cholesterol bound to albumin

up to 100 uCi of \[3H\]-cholesterol (containing approximately 0.2 mg of cholesterol) mixed with a solution containing human serum albumin will be administered as an intravenous bolus injection

Sponsors & Collaborators

Principal Investigators

  • Marina Cuchel, MD, PhD · University of Pennsylvania

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2024-09-04
Completion
2024-09-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01782027 on ClinicalTrials.gov